AdaptVac ApS: Financial statements 2019
CVR: 38732730
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 1,417,122 and a net result of DKK -185,145 compared with DKK 333,539 the year before. That is an increase of 228.1% compared with the year before. Equity in the 2019 report amounted to DKK -121,627. The company had 3 employees in the financial year.
- Gross Profit
- DKK 1,417,122
- Profit/Loss
- DKK -185,145
- Equity
- DKK -121,627
- Total Assets
- DKK 1,372,078
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
| 2018 | - | 432 t. | 334 t. | 64 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
AdaptVac ApS has published its annual report for 2018. Gross profit came to DKK 431,961, and the net result was DKK 333,539.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The board consists of Morten Agertoug Nielsen (chair), Adam Frederik Sander Bertelsen, Ali El-Salanti and Jacob Hjulmand. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. According to the 2025 annual report, the company had an average of 7 employees. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity in the 2025 report amounted to DKK 10,808,696.